glp-1 news november 2025 ISPOR 2025: Exploring reasons for discontinuation GLP-1 Agonists Weight Loss Drugs

Rodriguez, PhD, MPH Truveta, Inc , Bellevue, WA, Duy Do, PhD Truveta, Inc , Bellevue, WA, Nicholas Stucky, MD, PhD Truveta, Inc , Bellevue, WA Side effects were the most common reported reason for AOM and ADM GLP-1 RA discontinuation (28.2%)

This screening is a fundamental safety measure and should be documented in the patient's medical records

2018 Mar 16;9(3):167

These data indicated that oral d-allulose improved glucose tolerance via the GLP-1R

Most of the studies in fact, all the studies that we've seen now where we use patient-reported outcomes, meaning how's your physical functioning, in the trials they all go up across the board

[Internet] [DOI] [PMC free article] [PubMed] [Google Scholar] Ng M, Gakidou E, Lo J, Abate YH, Abbafati C, Abbas N, Abbasian M